{"filing":{"accession_number":"0001193125-26-280319","cik":"0001121404","ticker":"SNYNF","company_name":"Sanofi","form":"6-K","filing_date":"2026-06-24","report_date":null,"primary_document":"d118903d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312526280319/d118903d6k.htm"},"events":[{"id":13397,"run_id":11900,"accession_number":"0001193125-26-280319","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Sanofi announced regulatory approval of Sarclisa (isatuximab) subcutaneous formulation in Japan for multiple myeloma treatment, representing the second global approval for this formulation and a significant commercial milestone for the company's oncology portfolio.","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-24","form":"6-K","submitted_at":null,"items":[{"id":10527,"accession_number":"0001193125-26-280319","item_number":"EX-99.1","item_title":"d118903dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces regulatory approval of Sarclisa (isatuximab) subcutaneous formulation in Japan for multiple myeloma treatment. The approval is a material operational and commercial milestone for Sanofi's oncology portfolio, representing the second global approval for this formulation (following EU approval in June 2026) and expanding the product's market reach. The disclosure emphasizes clinical efficacy data from the IRAKLIA phase 3 study and the potential for Japan's first on-body injector administration of an anticancer therapy, which are significant product development and commercialization achievements rather than discrete financial, governance, or legal events.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-24T12:45:49.848495+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":13398,"run_id":11900,"accession_number":"0001193125-26-280319","anchor_item_number":"EX-99.2","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Sanofi announced the appointment of Paulo Fontoura as Executive Vice President, Global Head of Research \u0026 Development Pharma, effective September 1, 2026, with membership on the Executive Committee reporting to the CEO.","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-24","form":"6-K","submitted_at":null,"items":[{"id":10528,"accession_number":"0001193125-26-280319","item_number":"EX-99.2","item_title":"d118903dex992.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Sanofi announced the appointment of Paulo Fontoura as Executive Vice President, Global Head of Research \u0026 Development Pharma, effective September 1, 2026, with membership on the Executive Committee reporting to the CEO. This is a material C-suite appointment to lead the company's entire R\u0026D organization. The disclosure also notes the departure of his predecessor, Dr. Houman Ashrafian, but the principal disclosed action is Fontoura's appointment to this senior leadership role.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-24T12:45:49.848495+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":13399,"run_id":11900,"accession_number":"0001193125-26-280319","anchor_item_number":"EX-99.3","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"European Commission approved Cenrifki (tolebrutinib) for secondary progressive multiple sclerosis without relapses, representing a significant regulatory and commercial milestone for Sanofi's neurology pipeline.","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-24","form":"6-K","submitted_at":null,"items":[{"id":10529,"accession_number":"0001193125-26-280319","item_number":"EX-99.3","item_title":"d118903dex993.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces European Commission approval of Cenrifki (tolebrutinib) for secondary progressive multiple sclerosis without relapses, representing a significant regulatory and commercial milestone for Sanofi's neurology pipeline. While the approval itself is a material operational/regulatory achievement that would affect investor assessment of the company's product portfolio and growth prospects, it does not fit the discrete event categories of earnings_release (no financial results disclosed), ma_activity (no acquisition or merger), or other specific event types. The disclosure is clearly operational—a regulatory approval and product launch milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-24T12:45:49.848495+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":13400,"run_id":11900,"accession_number":"0001193125-26-280319","anchor_item_number":"EX-99.4","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Sanofi announced regulatory approval of Wayrilz (rilzabrutinib) in Japan for treating immune thrombocytopenia (ITP), based on successful LUNA 3 phase 3 clinical trial results, enabling market entry for this novel therapeutic.","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-24","form":"6-K","submitted_at":null,"items":[{"id":10530,"accession_number":"0001193125-26-280319","item_number":"EX-99.4","item_title":"d118903dex994.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces regulatory approval of Wayrilz (rilzabrutinib) in Japan for treating immune thrombocytopenia (ITP), granted by the Ministry of Health, Labour and Welfare. The approval is based on successful LUNA 3 phase 3 clinical trial results showing statistically significant platelet response and quality-of-life improvements. This is a material operational/commercial milestone—a regulatory approval enabling market entry for a novel therapeutic—but does not fit the specific event categories (not earnings, M\u0026A, litigation, or financial obligation). It represents a significant product commercialization event that would affect investor assessment of Sanofi's pipeline and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-24T12:45:49.848495+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10527,"accession_number":"0001193125-26-280319","item_number":"EX-99.1","item_title":"d118903dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces regulatory approval of Sarclisa (isatuximab) subcutaneous formulation in Japan for multiple myeloma treatment. The approval is a material operational and commercial milestone for Sanofi's oncology portfolio, representing the second global approval for this formulation (following EU approval in June 2026) and expanding the product's market reach. The disclosure emphasizes clinical efficacy data from the IRAKLIA phase 3 study and the potential for Japan's first on-body injector administration of an anticancer therapy, which are significant product development and commercialization achievements rather than discrete financial, governance, or legal events.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-24T12:45:49.848495+00:00","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-24"},{"id":10528,"accession_number":"0001193125-26-280319","item_number":"EX-99.2","item_title":"d118903dex992.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Sanofi announced the appointment of Paulo Fontoura as Executive Vice President, Global Head of Research \u0026 Development Pharma, effective September 1, 2026, with membership on the Executive Committee reporting to the CEO. This is a material C-suite appointment to lead the company's entire R\u0026D organization. The disclosure also notes the departure of his predecessor, Dr. Houman Ashrafian, but the principal disclosed action is Fontoura's appointment to this senior leadership role.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-24T12:45:49.848495+00:00","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-24"},{"id":10529,"accession_number":"0001193125-26-280319","item_number":"EX-99.3","item_title":"d118903dex993.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces European Commission approval of Cenrifki (tolebrutinib) for secondary progressive multiple sclerosis without relapses, representing a significant regulatory and commercial milestone for Sanofi's neurology pipeline. While the approval itself is a material operational/regulatory achievement that would affect investor assessment of the company's product portfolio and growth prospects, it does not fit the discrete event categories of earnings_release (no financial results disclosed), ma_activity (no acquisition or merger), or other specific event types. The disclosure is clearly operational—a regulatory approval and product launch milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-24T12:45:49.848495+00:00","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-24"},{"id":10530,"accession_number":"0001193125-26-280319","item_number":"EX-99.4","item_title":"d118903dex994.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces regulatory approval of Wayrilz (rilzabrutinib) in Japan for treating immune thrombocytopenia (ITP), granted by the Ministry of Health, Labour and Welfare. The approval is based on successful LUNA 3 phase 3 clinical trial results showing statistically significant platelet response and quality-of-life improvements. This is a material operational/commercial milestone—a regulatory approval enabling market entry for a novel therapeutic—but does not fit the specific event categories (not earnings, M\u0026A, litigation, or financial obligation). It represents a significant product commercialization event that would affect investor assessment of Sanofi's pipeline and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-24T12:45:49.848495+00:00","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-24"}]}